Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Inostamycin A is a bacterial metabolite that has been found in Streptomyces and has anticancer activity.1 It is an inhibitor of CDP-diacylglycerol:inositol 3-phosphatidyltransferase (IC50 = 0.02 µg/ml in A431 cell membranes) and is selective for CDP-diacylglycerol:inositol 3-phosphatidyltransferase over phospholipase C (PLC) and phosphatidylinositol kinase at 10 µg/ml.2 Inostamycin A decreases viability of YCU-T892, KCC-TC873, KB, HSC-4, and YCU-T891 oral squamous cell carcinoma (OSCC) cells in a concentration-dependent manner.3 It induces cell cycle arrest in the G1 phase in HSC-4 cells when used at a concentration of 250 ng/ml and induces apoptosis in Ms-1 small cell lung cancer cells at 300 ng/ml.3,4 Inostamycin A also reduces levels of matrix metalloproteinase-2 (MMP-2) and MMP-9 and inhibits EGF-induced migration of HSC-4 cells.5
WARNING This product is not for human or veterinary use.
1. Isolation and structure determination of inostamycin, a novel inhibitor of phosphatidylinositol turnover. J. Nat. Prod. 53(4), 825-829 (1990).
2. Inhibition of CDP-
3. Cytostatic effect of inostamycin, an inhibitor of cytidine 5'-
4. Inhibition of cyclin D1 expression and induction of apoptosis by inostamycin in small cell lung carcinoma cells. Jpn. J. Cancer Res. 89(3), 315-322 (1998).
5. Inostamycin, an inhibitor of cytidine 5'-